Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

McMaster University

$71,105.00

Engineering Starch-Based Nanoparticles and Nanoparticle Clusters for Improving Local Drug Delivery to Tumour Cores and the Brain

EF 2017-18

Résumé
Delivering drugs using nanoparticles has been demonstrated in multiple cases to improve theability of drugs to get to their target sites, particularly in cases in which drugs must betransported inside cells to be functional and/or drug must be transported from the bloodthrough hard-to-penetrate biological barriers (e.g. into the brain or through dense tissues suchas tumour masses). Starch nanoparticles (SNPs), developed by our partner EcoSynthetix,have particular potential for drug delivery in this context given their capacity for direct loadingof drug during fabrication, their extremely small sizes, their gel-like properties (and thuspotential to deform under stress), and their biological inertness. However, there are twoinherent limitations to using SNPs for drug delivery: (1) drug release from SNPs is very fastgiven their porous structures and (2) the small size of SNPs, while ideal for penetrating intothe brain or deep into tumours, also induces relatively fast clearance of SNPs from normalcirculation, restricting the capacity of SNPs to transport drugs to target sites. In this proposal,we aim to address these challenges by (1) engineering the surface of SNPs to adjust drugrelease rates to desired values and (2) developing methods of fabricating controlled clustersof SNPs with good circulation properties that can be selectively degraded where drug releaseis desired (either by specific chemistry at the target site or by external activation after aspecific time). We anticipate that such SNP-based materials will significantly improve thedelivery of drugs not only deep inside tumours and both into and within the brain (our twoproof-of-concept demonstrations) but also other diseases in which effective therapy is limitedby drug transport. Such capacity is anticipated to both improve health outcomes forCanadians suffering from such diseases as well as provide a new, value-added market toEcoSynthetix that will promote new job creation in Canada.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
508393-2017
Name nom
Hoare, Todd
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
71105
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Engineering Starch-Based Nanoparticles and Nanoparticle Clusters for Improving Local Drug Delivery to Tumour Cores and the Brain
Keyword
NSERC
Application summary
Delivering drugs using nanoparticles has been demonstrated in multiple cases to improve theability of drugs to get to their target sites, particularly in cases in which drugs must betransported inside cells to be functional and/or drug must be transported from the bloodthrough hard-to-penetrate biological barriers (e.g. into the brain or through dense tissues suchas tumour masses). Starch nanoparticles (SNPs), developed by our partner EcoSynthetix,have particular potential for drug delivery in this context given their capacity for direct loadingof drug during fabrication, their extremely small sizes, their gel-like properties (and thuspotential to deform under stress), and their biological inertness. However, there are twoinherent limitations to using SNPs for drug delivery: (1) drug release from SNPs is very fastgiven their porous structures and (2) the small size of SNPs, while ideal for penetrating intothe brain or deep into tumours, also induces relatively fast clearance of SNPs from normalcirculation, restricting the capacity of SNPs to transport drugs to target sites. In this proposal,we aim to address these challenges by (1) engineering the surface of SNPs to adjust drugrelease rates to desired values and (2) developing methods of fabricating controlled clustersof SNPs with good circulation properties that can be selectively degraded where drug releaseis desired (either by specific chemistry at the target site or by external activation after aspecific time). We anticipate that such SNP-based materials will significantly improve thedelivery of drugs not only deep inside tumours and both into and within the brain (our twoproof-of-concept demonstrations) but also other diseases in which effective therapy is limitedby drug transport. Such capacity is anticipated to both improve health outcomes forCanadians suffering from such diseases as well as provide a new, value-added market toEcoSynthetix that will promote new job creation in Canada.